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Abstract: The emergence of oral disease-modifying therapies in multiple sclerosis (MS) will 
have a significant impact on the evolving scenario of immunomodulatory treatments in MS 
where current therapies are all injectable. Reducing relapses in trials translates for individuals 
with MS into a therapeutic aim of stopping future events. Thus the possible absence of any 
perceived benefits to the individual together with the long disease course, variable outcome, 
and a younger age group affected in MS makes side effects the major issue. The use of disease-
modifying therapies as a whole needs to be placed in the context of a widening therapeutic 
indication where the use of these therapies is being justified at an increasingly early stage and 
in pre-MS syndromes such as clinically isolated and radiologically isolated syndromes where 
no fixed disability is likely to have accumulated. The five oral therapies discussed (cladribine, 
fingolimod, laquinimod, BG-12, and teriflunomide) have just completed Phase III studies and 
some have just been licensed. New oral drugs for MS need to be placed within this evolving 
marketplace where ease of delivery together with efficacy and side effects needs to be balanced 
against the known issues but also the known long-term safety of standard injectables.
Keywords: multiple sclerosis, immunomodulatory treatment, cladribine, fingolimod, 
  laquinimod, BG-12, teriflunomide
Introduction to management issues in treatment  
of MS – new developments with oral agents
Multiple sclerosis (MS) is the most common central nervous system (CNS) demyelinating 
disease worldwide. The disease incidence ranges from 2 to 10 per 100,000 population 
per year and has a prevalence of 100 to 150 per 100,000 in the UK, making MS the 
most common non-traumatic acquired cause of disability in young adults.1,2
Interferon beta (IFN-β), the first therapy in randomized trials to reduce the num-
ber of relapses that people with MS experience, has revolutionized the management 
of the condition, introducing the concept of disease-modifying treatment (DMT). 
  However, as yet, DMTs have not influenced the long-term prognosis3 and their role in 
the   management of MS remains under challenge in some health systems.4
The confirmation that relapses can be reduced by therapy has driven attempts to 
diagnose the condition earlier and has also paved the way for other DMTs, includ-
ing glatiramer acetate (GA)5 and natalizumab.6 Until recently all available therapies 
were injectable, a key disadvantage both for patients in terms of side effects and for 
health services in terms of cost, but, based on results of large randomized controlled 
double-blind trials, a number of oral therapies are becoming available. Their position Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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in management of MS is yet to be determined but will 
emerge during the next few years as their use becomes more 
widespread.7
In this article, we will introduce the evolving scenario 
of immunomodulatory treatments, starting with an overview 
of injectable therapies. We will then review five new oral 
immunomodulatory agents that have been recently investi-
gated in clinical trials, with a main focus on fingolimod and 
cladribine, the two oral drugs that are at the most advanced 
stage of development and that have already, or soon will 
have been, submitted for marketing authorization in several 
countries, and that have already been approved in some 
countries (at the time of writing, the US for fingolimod and 
Russia and Australia for cladribine).
when does relapsing-remitting MS start?
The development of DMTs that have effects on relapses 
has probably exerted some role in the refinement of the 
diagnostic criteria for MS in an attempt to identify the 
condition at an early stage – “McDonald criteria” MS.8 
Subsequent evidence that early treatment with potent immu-
notherapy can stop and even reverse the accumulation of 
disability9,10 together with evidence that relapses occurring 
within the first 2 years have some influence on prognosis,11 
provides further support to the rationale of early treatment 
of MS.   Identifying disease   activity earlier has led to the 
  emergence of the “clinically isolated   syndrome” (CIS)12 
and the   “radiologically isolated   syndrome” (RIS)13 as 
potential predictors of   relapsing-remitting (RR) MS where 
therapeutic intervention may have a role   (Figure 1). This 
approach together with “rapidly evolving severe” (RES) MS, 
a subgroup identified by some funders,14 identifies 5 clinical 
scenarios that offer a potential target for a therapy aimed at 
reducing relapses (Table 1).
Relapse-modifying therapy – treat  
early or never?
The drive behind identifying the disease early is the under-
standing that “relapse-modifying” therapy initiated in the 
progressive phase does not stop progression.15 Therefore 
treatment early in the disease can have significant benefi-
cial long-term benefits, but if treatment is delayed, though 
entailing the same risk, and no matter how small, will have 
no benefit (Figure 2).
Much of the work in the field of “immune resetting” has 
been undertaken on the evaluation of aggressive therapies 
where their effects need to be balanced against our lack 
of ability to predict outcome with a disease course that 
can have a median length of 50 years, depending upon the 
  population.16 The onset in the majority can be relatively 
Clinical
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Figure 1 Attempts to identify disease activity earlier than clinically definite relapsing-remitting MS (RRMS) has resulted in the identification of “McDonald Criteria” MS, 
clinically isolated syndrome (CIS), and radiologically isolated syndrome (RIS) based around MRI.
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benign, but   disability can still accumulate progressively after 
many years in 43% to 89% of people with MS. However, 
10% to 15% will never experience any disability and treat-
ing all will expose a significant minority to therapy that is 
not required.16 The relationship of CIS and RIS with final 
disability currently is even less clear.
Though early relapse rates have a limited predictive 
ability in MS,11 other features that predict severity such 
as B-cell follicle-like structures have been found only at 
post-mortem.17 Otherwise, the onset of early disability is 
unquestionably   significant, but once a certain level is reached 
relapse-modifying therapy does not prevent progressive 
deterioration.18,19 Thus there is limited potential to initiate a 
successful therapy based on reducing relapses.
Therefore the clinical drive is to identify those at risk 
of poor outcomes early in the course of disease, given the 
potential need for a durable therapeutic effect, with its asso-
ciated risks, for many years. However the reality is that our 
current knowledge of MS prognosis and of both long-term 
efficacy and safety of DMTs is limited and treatment needs 
be considered with equipoise.
A changing study population
An increasingly acknowledged problem of incorporating 
the results of new studies into all types of MS therapy is the 
issue of a changing population who enter trials. As therapies 
have been introduced into practice and people with MS 
have started them, those who did not are either viewed by 
  themselves and/or their doctor as benign cases or have issues, 
up to now, with injectables. As a result the relapse rate evident 
in trials has declined over time,20 presenting challenges for 
clinical trial design21 (Figure 3).
This trend has two major implications for the clinical 
  management of MS. Firstly this problem has been identi-
fied by funders and has led to the identification of a RES 
subgroup of RRMS (Table 1). Actually, the criteria for RES 
define a population that formed a substantial subgroup of 
those who took part in early randomized trials of DMTs in 
MS. The second issue is applicability of trial outcomes across 
the early onset subtypes with a genuine need to identify the 
benefits/risk balance in subjects commenced on any therapy 
(Table 1).
Summary
Injectable relapse-modifying therapies for MS are well 
established in the management of MS. The development of 
oral therapies needs to be placed in the context of a number 
of ongoing patient management issues in MS. Beyond clini-
cally definite RRMS there are a number of areas where their 
use may be applied but this involves extrapolation of trial 
data and assumptions about the role of immune interven-
tions (Table 2). The acceptability of the risks of therapy 
compared with the potential benefits will vary in differ-
ent countries according to different standards of practice, 
Table 1 Pre-MS and MS subtypes as potential targets for oral therapies
RRMS subtype Definition Risk of second episode/ARR over 2 years
Pre-MS
RiS13 Inflammatory lesions on MRI in the absence of clinical 
symptoms indicative of a related neurological episode
RiS could underlie the subsequent development 
of RRMS or PPMS
31% (52/166)169
CiS12 A single inflammatory neurological event. Subdivided 
based on number of MRi lesions present initially 
MRi: ,three lesions on MRi there is a ,10% risk 
of MS at 15 years. if $three lesions the risk 
of MS is 50% at 15 years
,3 MRi lesions: 10% 
$3 MRi lesions: 45%170
MS
“McDonald Criteria” MS8 Single neurological episode with MRi evidence of 
dissemination in time and space
41%171
Clinically definite MS Two relapses disseminated in time and space. 
Group 1: CDMS from 1996, Group 2: CDMS from 2008
Group 1: 1.2 relapses/year 
Group 2: 0.5 relapses/year21
ReS RRMS14 Two clinically significant relapses in one year and one 
or more gadolinium-enhancing lesions on brain MRi 
or a significant increase in T2 lesion load 
1.46 relapses/2 year172
Note: Risk of second episode and ARR are based on trial placebo data.
Abbreviations: ARR, annualized relapse rate; CiS, clinically isolated syndrome; ReS, rapidly evolving severe; RiS, radiologically isolated syndrome; RRMS, relapsing-remitting 
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health systems, and applicable policies. The challenge for 
  clinicians, scientists, and regulatory authorities is how to best 
use the current knowledge about distinct disease subtypes 
and natural history studies to deliver the optimal benefit for 
people with MS.
Overview of the standard 
injectables for MS treatment
Four major classes of standard injectables are used in the 
treatment of MS. These include IFN-β, GA, natalizumab, 
and mitoxantrone. Other less commonly used therapies 
include intravenous immunoglobulin and the oral agent 
azathioprine (reviewed by Nicholas and Chataway).22
interferon-β (IFN-β)
Mode of action
IFN-β is a type I interferon that has anti-viral and anti-
  inflammatory characteristics. The mode of action is to inhibit 
T-cell activation and reduce the blood–brain   barrier (BBB) 
permeability to inflammatory cells.23 Two   types of IFN-β   
A
B
Axonal injury
Clinical disability
Inflammation Neurodegeneration
Reset immune tolerance
Inflammatory
activity
Preclinical Relapsing-Remitting
Preclinical Relapsing-Remitting
Secondary Progressive 
Axonal injury
Clinical disability
Inflammation Neurodegeneration
Reset immune tolerance
Inflammatory
activity
Figure 2 Resetting immune tolerance can prevent subsequent disability (A); however evidence is emerging that beyond a certain point during the course of MS, a   “relapse-
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are available (IFN-β1b and IFN-β1a). Their main difference 
is in their pharmacokinetics and pharmacodynamics.24
Efficacy
In RRMS (two relapses in the previous 2 or 3 years) IFN-β 
reduces relapse rates by ∼30% compared with placebo25 as 
well as reducing lesion accumulation on the magnetic reso-
nance imaging (MRI) scan.26 In CIS, three studies have found 
that IFN-β significantly reduces the risk of a second event and 
therefore of conversion to clinically definite MS.27–29
Side effects
Few serious adverse events are associated with IFN-β25 
though there is a risk of hepatic injury.30 Early flu-like 
symptoms occur in 50% of people but injection site reactions 
occur with subcutaneous administration in 80% of people. 
There is evidence that neutralizing antibodies to IFN-β that 
can develop after 1 year of therapy and is one cause of reduc-
tion in efficacy of the drug.31 Unfortunately, the parenteral 
mode of administration is a leading cause for compliance 
and tolerability problems in many patients.32,33
Glatiramer acetate (GA)
Mode of action
GA is a random combination of four amino acids (alanine, 
lysine, glutamate, and tyrosine)34 which has a structural 
similarity to myelin basic protein. GA is an immune 
  modulator, working, it is thought, by shifting the T helper 
(Th)1 lymphocytes in MS patients towards a predominance 
of Th2 phenotype. It represents the first successful use of an 
agent that ameliorates MS autoimmune responses by altering 
  signals through the T cell receptor.35
Efficacy
GA, subcutaneously administered on a daily basis to patients 
with RRMS, significantly reduced relapse rates by ∼30% 
over 2 years compared with placebo5,36 and prevented the 
appearance of new lesions detectable by MRI.36,37   Comparator 
studies against IFN-β have shown no difference.38,39 GA also 
significantly reduces the time to conversion to clinically 
definite MS from CIS.40
Side effects
There are no major adverse reactions but a self-limiting 
allergic-type reaction (flushing, chest tightness, and anxiety) 
can occur in 15% of people taking GA.36 Local injection site 
reactions are increased compared with placebo, occurring in 
up to 80% of people.5
Natalizumab
Mode of action
Natalizumab is a monoclonal antibody to the α4 subunit of 
α4β1 integrin (VLA-4), a protein found on the surface of 
lymphocytes. α4β1 integrins interact with the vascular-cell 
adhesion molecule 1 enabling adhesion of lymphocytes to the 
vascular endothelium. Its main mode of action is to prevent 
the transmigration of inflammatory lymphocytes across the 
BBB into the CNS.41
Efficacy
Clinical trials confirmed that natalizumab produced a 68% 
reduction in annualized relapse rate, 92% reduction in 
gadolinium enhancing lesions in MRI, and a 42% reduc-
tion in   disability progression rate over 2 years compared 
with   placebo.6 Natalizumab reduced relapse rates by 53% 
in combination with IFN-β1a compared with IFN-β1a 
monotherapy.42 To our knowledge natalizumab has not been 
studied in CIS populations.
Side effects
After obtaining its license in 2005 natalizumab was with-
drawn when three fatal progressive multifocal leukoenceph-
alopathy (PML) cases were associated with combination 
therapy with IFN-β1a. It was subsequently reapproved as 
monotherapy for MS after safety re-evaluation.43 The esti-
mated risk of PML with natalizumab is 1 in 1000 (0.1%).44 
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Figure 3 Annualized relapse rates observed in the 26 trials identified in the systematic 
review by Nicholas et al21 plotted against the year in which the paper was published. 
The dashed line shows the fitted trend line.
Adapted from Nicholas et al.21 Copyright © 2011, SAGe Publications. http://msj.
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Neutralizing antibodies, which cause loss of drug efficacy, 
have been identified in about 6% of patients.45
Mitoxantrone
Mode of action
Mitoxantrone is an anthrecenedione immunosuppressive 
cytotoxic agent that acts on a number of possible pathways, 
including inhibition of T-cell activation, suppression of 
T-cell, B-cell and macrophage proliferation, impaired 
antigen presentation, prevention of macrophage medi-
ated   demyelination, and reduction of pro-inflammatory 
cytokines.46
Efficacy
Clinical trials have supported the use of mitoxantrone for 
the treatment of worsening RRMS, progressive relapsing 
MS, and secondary progressive (SP) MS.47–49 Mitoxantrone 
significantly reduced relapse rates per year at 2 years by 
69% and significantly reduced the proportion of people with 
sustained disease progression at 2 years.47
Side effects
The major risks are dose-related cardiotoxicity and leukemia. 
The risk of congestive heart failure exceeds 0.20% with a 
mean cumulative dose of (60.5 mg/m2); in addition 2.2% of 
patients showed an asymptomatic reduction in left ventricular 
ejection fraction.50 The risk of leukemia varies but has been 
found to be as high as 0.67%.51 Over a quarter of women 
taking mitoxantrone developed amenorrhea compared with 
none taking placebo, 8% of whom were still experiencing 
this at the end of the trial. Nausea and vomiting, alopecia, and 
urinary tract infections were more frequent in people taking 
mitoxantrone.
Using the standard injectables
Recommendations for starting injectable therapies in RRMS 
vary worldwide. In the UK, despite evidence, injectables 
are not usually commenced until the development of 
  clinically definite RRMS, whereas in the US they are used 
in RIS.   Generally IFN-β or GA is commenced as first-line 
  medication. Treatment failure would indicate transferring 
either to the alternative first-line therapy or to second-line 
treatments such as natalizumab if the patient has definite 
RRMS (or RES RRMS in the UK) or mitoxantrone where 
progression may be starting. However there is no fixed 
therapeutic pathway and with licensing of natalizumab in 
the UK it can be prescribed as first-line pharmacotherapy if 
patients fulfill the relevant criteria.14
Pharmacodynamics and 
pharmacokinetics of the 
new oral agents
Cladribine
Mode of action
Cladribine is a synthetic purine nucleoside analog that 
produces selective lymphocyte depletion through inhibi-
tion of cellular DNA synthesis and repair.52,53   Lymphocyte 
damage arises from the accumulation of cladribine active 
triphosphate deoxynucleotide, produced by high lev-
els of deoxycytidine kinase, and poorly metabolized by 
5′-nucleotidase;54   furthermore cladribine metabolites are 
resistant to   degradation by adenosine deaminase.55
The peculiar balance of enzymes required for the metabo-
lism of purine nucleoside determines cladribine’s specificity 
for particular immune cell types. Hence, cladribine affects 
both B and CD4 and CD8 T lymphocytes, with minor 
effects on natural killer, null, and innate immune cells.53,56 
Table 2 Using data from placebo groups over 2 years based on 100 subjects in each group to predict the number of expected relapses
Efficacy Relapse reduction 30% 30% 50% 70%
example therapy iFN-β, GA terifluonamide cladribine/fingolimod natalizumab/mitoxantrone
Side effects (%) serious 0 0.1 0.8/0.8 0.1/0.7
ongoing 80% minimal minimal minimal
expected relapses with therapy over 2 years
Demyelination syndrome 
subtype (expected 
relapses in 2 year period)
Rapidly evolving severe (300) 210 210 150 90
Clinically definite – group 1 (240) 168 168 120 72
Clinically definite – group 2 (100) 70 70 50 30
McDonald (41) 29 29 21 13
CiS $ 3 MRI lesions (45) 32 32 23 14
,3 MRI lesions (10) 7 7 5 3
RIS (31) 22 22 16 10
Notes: Using trial efficacy data the relapses that will occur as result of therapy can be predicted. Acceptability is highlighted: green, acceptable in most health systems; orange: 
acceptable in US/parts of Europe; red: not acceptable in health systems due to side effects; grey outline: groups in trials that have been tested.
Abbreviations: CiS, clinically isolated syndrome; RiS, radiologically isolated syndrome; GA, glatiramer acetate.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Cladribine also impairs the migratory capacity into the CNS 
via the BBB and within the CNS of CD4 and CD8 T lympho-
cytes and, to a lesser extent, CD14 monocytes,57 Cladribine 
also reduces the production of the proinflammatory cytokine 
interleukin (IL)-2 and chemokines.58–60
Pharmacokinetics
Cladribine is a pro-drug that needs intracellular phosphoryla-
tion to activate nucleotides, and it is the intracellular concen-
tration of these metabolites, which is several hundred-fold 
higher than that of cladribine in plasma, that is important. 
There is no correlation between the plasma concentra-
tion of cladribine and that of the intracellular metabolites, 
  however, much of the pharmacokinetic data on cladribine 
was derived after subcutaneous and intravenous adminis-
tration   (2-chloro-2′-deoxyadenosine). After subcutaneous 
administration the cerebrospinal fluid concentration is 25% 
of that in plasma in healthy subjects, whereas in patients with 
meningeal disease, cladribine concentration in the cerebro-
spinal fluid exceeds that of plasma. This is relevant in MS 
because BBB breakdown in active disease phases will result 
in higher CNS bioavailablity.61 The distribution of intrave-
nous cladribine in patients with hematological malignancies 
showed a plasma protein binding of 25% (21.1% in healthy 
controls) and a volume of distribution of 6.57 L/kg.62
The oral preparation used in RRMS has a new dosage 
form (with 2-hydroxypropyl- β-cyclodextrin; HPβCD) 
containing 3 mg or 10 mg of cladribine. Absorption of this 
preparation has a peak in 0.5 to 1.5 hours, being slightly 
delayed when administered with a high-fat meal. After 
administration of 10 mg tablet, the bioavailability is 39% 
to 43% and 28.5% is eliminated via the renal route, with a 
renal clearance of 29.9 L/h.63
Pretreatment with cladribine increases the intracellular 
accumulation of the active metabolite of cytarabine, cytosine 
arabinoside 5’-triphosphate, by 36% to 40%, which supports 
the use of an annual, short-course dosing regimen.61
Fingolimod
Mode of action
Fingolimod is the first of a new class of drugs that inhibits 
immune cell migration by interacting with sphingosine 
1-phosphate (S1P) receptors. S1P binds to S1P receptors 
predominantly on lymphocytes, signaling for them to exit 
lymph nodes and enter the circulation.64 S1P also regulates 
diverse cellular functions such as survival and proliferation.65 
S1P receptors belong to a G protein–coupled receptor family 
(S1P1-S1P5) which are targeted by fingolimod–phosphate 
(fingolimod-P) 66 an active metabolite that arises from the 
reversible phosphorylation of fingolimod by sphingosine 
kinase.67
With initial dosing of fingolimod, there is agonism of 
S1P receptors and transient signaling.68 However, with 
continued fingolimod dosing, functional antagonism occurs 
with internalization of S1P receptors.69 Nevertheless, S1P1 
receptors activated by fingolimod-P retain signaling activity 
for hours in spite of a quantitative internalization. The ulti-
mate effect, however, is to prevent the egress of lymphocytes 
from lymphoid organs, including self-reactive circulating 
lymphocytes, but lymphocytes persist in central lymph nodes, 
maintaining a reactivity in systemic infection.64,68,70 Besides 
in lymphocytes, the presence of S1P1 receptors in endothe-
lial cells is reported to contribute to the egress prevention 
of lymphocytes.71–73
Pharmacokinetics
After oral administration (1.25 mg) in man there is a median 
0.5 hours before fingolimod appears in blood at quantifi-
able levels. An initial absorption “shoulder” occurs in 
4 hours and the peak of 1.1 ng/mL is reached 12 hours after 
dosing.74,75 Its absorption is not affected by food, regardless 
of the fat content.76 The area under the concentration-time 
curve extrapolated to infinite time (AUC) is 85% ± 6% and 
the absolute oral bioavailability is 94%. Fingolimod and 
fingolimod-P have a red blood cell distribution respectively of 
86% and ,17% and are both highly protein bound, .99.7% 
with an extensive volume of distribution of 1200 ± 260 L. 
Steady state blood concentrations are reached after 2 months 
of daily dosing and during maintenance dosing, the conver-
sion between fingolimod and fingolimod-P yields a stable 
blood level ratio of the two moieties.
The biotransformation of the fingolimod metabolites 
occurs through three pathways.
One is the reversible phosphorylation to fingolimod-P 
mainly through the action of sphingosine kinase type 2 
with a lesser contribution from sphingosine kinase type 1. 
Reverse dephosphorylation to fingolimod occurs through 
the action of the lipid phosphate phosphohydrolases 
(LPP)1a and LPP3 and to a lesser extent by the specific 
sphingosine 1-phosphate phosphatase SPP1. The second 
pathway is the fingolimod oxidative biotransformation, 
through cytochrome (CYP)4F2 hydroxylation, resulting 
in the M12 metabolite, followed by M1, M2, M3, and M4. 
The third pathway involves transformation by the dihydro-
ceramide synthase to form the nonpolar metabolites M29, 
M30, M27, and M28.77Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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The steady-state oral clearance of fingolimod   averages 
10.8 L/h and its half-life is 6.1 ± 1 days. After an oral admin-
istration, about 81% of the dose is slowly excreted in the 
urine as inactive metabolites, and after 34 days 89% of the 
administered dose can be recovered.74,75
BG-12
Mode of action
The exact mechanism of action by which the oral formula-
tion of dimethylfumarate (DMF) and monomethylfumarate 
(MMF), its primary metabolite, exert their effects in MS is 
still unclear. In vitro experiments indicate three potential 
pathways of action. First, BG-12 has been found able to 
switch the T-helper response from Th1 to Th2 phenotype,78 
both increasing the Th2 driving molecules, such as IL-4, 
IL-10, and IL-5,79–82 and reducing the Th1 driving molecules, 
IL-6, IL-1β and tumor necrosis factor (TNF) alpha,81,83–87 
The second pathway involves the activation of the nuclear 
factor E2-related factor 2 (Nrf2) transcriptional pathway,88 
which acts on one side as an oxidative stress modulator by 
the induction of phase II detoxification genes.87,89,90   Treatment 
of cultured astroglia and microglia with fumaric acid esters 
enhances the activity of phase II detoxification enzyme 
NAD(P)H:quinone oxidoreductase-1 (NQO-1) mRNA, and 
increases the cellular glutathione content of activated mixed 
glial cells.86 On the other side the Nrf2 has neuroprotective 
capabilities such as inhibition of excitotoxic and oxidative 
neuronal damage,91–95 BBB protection,96 and regulation of 
myelin maintenance.97 Through the third pathway, DMF 
almost completely inhibits the TNF-induced CD62E, 
responsible for the accumulation of blood leukocytes at sites 
of inflammation by mediating the adhesion of cells to the 
vascular lining.84 These data suggest that BG-12 could have 
dual neuroprotective and anti-inflammatory effects.
Pharmacokinetics
After oral intake, DMF is rapidly hydrolyzed by esterases 
to its metabolite MMF. Completely absorbed in the small 
intestine,86 it can interact with immune cells in the blood 
circulation.83 MMF, the most bioactive metabolite,98 is further 
metabolized in the citrate cycle to carbon dioxide and water 
and finally eliminated mainly though breathing, while only 
small amounts of intact MMF are excreted through urine or 
feces. The half-life of DMF and MMF are about 12 minutes 
and 36 hours, respectively. The peak concentration of MMF 
in human serum is reached 5 to 6 hours after oral intake. 
There is no evidence for a cytochrome P450-dependent 
metabolism in the liver.99
Laquinimod
Mode of action
Laquinimod is a new synthetic immunoregulator derived from 
roquinimex but is pharmacologically and chemically distinct 
from its progenitor; the clinical Phase III trial of roquinimex 
was stopped due to side effects.100–102 Chemical modifications 
of the roquinimex structure have given laquinimod a favorable 
pharmacology/toxicology profile. In addition to being a more 
potent disease inhibitor,103 with better tolerability, the effects 
on the immune system have become increasingly clear.
Initial evidence of its immunomodulatory effects dem-
onstrate that laquinimod biases the CD4+ phenotype in 
favor of the Th2/Th3 cytokine production IL-4, IL-10, and 
transforming growth factor-b and inhibits disease develop-
ment and infiltration of inflammatory cells, CD4+ T cells, 
and macrophages, into the CNS.104,105 Another effect on the 
immune system is the suppression of major histocompat-
ibility class II antigen presentation and down-regulation of 
epitope spreading.106
The effect of laquinimod treatment is not dependent on 
endogenous IFN-β for its disease inhibition in chronic experi-
mental autoimmune encephalomyelitis (EAE), but combined 
with exogenous IFN-β for treatment of chronic EAE a signifi-
cant synergistic inhibitory effect was seen.107 Lymphocytes 
from laquinimod-treated animals displayed reduced VLA-
4-mediated adhesiveness, without suppression of spontane-
ous and antigen-induced T-cell proliferation;108 laquinimod 
reduces chemotaxis and adhesion molecules through the 
suppression of the nuclear factor kappa-light-chain-enhancer 
of activated B cells (NFκB) pathway that interact with the 
apoptotic activation of immuno-competent cells.106
Pharmacokinetics
Laquinimod has high oral bioavailability, small volume of 
distribution, and a low total clearance rate. The peak plasma 
concentration is reached within 1 hour of oral administration. 
Laquinimod is metabolized as a low affinity substrate for 
CYP3A4 in liver microsomes. Four hydroxylated and two 
dealkylated products are cleared primarily through the urine 
and are not metabolically active. Less than 5% of laquinimod 
is eliminated unchanged in urine or feces. Strong specific 
inhibitors of the CYP3A4 enzyme such as ketoconazole can 
slow the elimination of laquinimod.109
Teriflunomide
Mode of action
Teriflunomide is a reversible non-competitive inhibitor of 
dihydroorotate dehydrogenase (DHODH),110,111 an integral Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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mitochondrial membrane protein essential for pyrimidine 
synthesis.112,113 Inhibiting DHODH prevents clonal expansion 
of B and T cells and antibody production.114–116 Consistent 
with its tyrosine kinase inhibitory properties, further immu-
nomodulatory effects have been reported, such as the block 
of immunoglobulin (Ig) G1 production from IgM isotype 
switching after IL-4 receptor stimulation;117 inhibition of 
calcium mobilization in lymphoma cells stimulated by anti-
CD3 antibody, IL-2 production, IL-2 receptor expression 
on human T lymphocytes, and tyrosine phosphorylation in 
CTLL-4 cells stimulated by IL-2;118 and diminished activation 
of inducible nitric oxide synthase in astrocytes.119
Pharmacokinetics
The pharmacokinetics of teriflunomide, appear to be linear 
over the therapeutic dosage range. Mean plasma half-life is 
15 to 18 days and the bioavailability is nearly 100%, with 
total plasma clearance of 0.30 mL/kg/hour. It is extensively 
protein bound (.99%) primarily to albumin, with an almost 
constant portion (0.5%) of free teriflunomide, and cleared 
via several metabolic pathways, including biliary and urinary 
excretion.120
Clinical efficacy, tolerability,  
and safety of the new oral agents
Cladribine
Clinical efficacy
Parenteral cladribine has been studied in progressive and 
relapsing MS in three randomized, double-blind, placebo-
controlled trials. The first, a 2-year crossover study evaluating 
the clinical and radiological efficacy of intravenous cladrib-
ine in 51 chronic progressive MS subjects, started in 1992. 
In the first year the treatment arm was given four monthly 
courses of 0.10 mg/kg/day for 7 days, a total of 2.8 mg/kg of 
cladribine. In the second year patients treated with placebo 
in the first year were given a half dosage of cladribine in 
three successive monthly courses of 0.10 mg, 0.05 mg, and 
0.05 mg/kg/day for 7 days. This study showed that cladrib-
ine could temporarily stabilize clinical progression, with a 
possible dose-dependent effect. There was a reduction in 
enhancing lesions on MRI (absent at 1 year in 22 out of 24 
treated versus 12 out of 24 placebo subjects, P , 0.001), but 
no significant change in T2 lesion load.121 The second study 
was an 18-month study in 52 RRMS patients who received 
placebo or cladribine at 0.07 mg/kg/day by subcutaneous 
injection for five consecutive days as six monthly courses 
achieving a total dose of 2.1 mg/kg. Patients were followed 
up for further 12 months. Those receiving cladribine had 
a significant reduction in a combined measure of the severity 
and frequency of relapses compared with patients receiv-
ing placebo from months 7 to 12, which was maintained at 
month 18. There was a significant reduction in enhancing 
lesions on MRI at 6 months after treatment that was main-
tained at 12 and 18 months compared with placebo.122 In the 
third study 159 patients with progressive MS (30% primary, 
70% secondary) received placebo or subcutaneous injection 
of cladribine at 0.07 mg/kg/day for five consecutive days 
every four weeks for either two or six cycles (total dose, 
0.7 mg/kg or 2.1 mg/kg, respectively), followed by placebo, 
for a total of eight cycles. This study confirmed cladribine’s 
ability to suppress enhancing lesions on MRI. The higher 
dosage also reduced the accumulation of T2 lesions, but both 
doses failed to affect disability progression.56
In the light of these results, three trials were designed in 
order to assess the effectiveness of oral cladribine in RRMS. 
In the first, CLARITY (CLAdRIbine Tablets Treating MS 
OrallY), 1326 patients were enrolled in a 1:1:1 ratio to receive 
one of two cumulative doses of cladribine tablets (either 
3.5 mg or 5.25 mg/kg body weight) or matching placebo, 
given in two or four short courses for the first 48 weeks, then 
in two short courses starting at week 48 and week 52 (for 
a total of 8 to 20 days per year). During the 96-week study, 
patients receiving 3.5 and 5.25 mg/kg showed, respectively, 
versus placebo, a relative reduction in annualized relapse rate 
of 57.6% and 54.5%, a higher relapse-free rate (odds ratio: 
2.53 and 2.43), an increased time to first relapse (hazard 
ratio [HR] 0.44 and 0.46), a lower risk of 3-month sustained 
progression of disability (HR 0.67 and 0.69), and a relative 
reduction of enhancing lesions of 85.7% and 87.9% and of 
active T2 lesions of 73.4% and 76.9%.23 This study has been 
extended for 2 years, so that patients originally randomized to 
placebo in the CLARITY study will all receive two courses 
of oral cladribine per year. Patients in either of the cladribine 
groups will be randomized 2:1 to receive two courses of 
cladribine per year or placebo. Patients will maintain the same 
treatment for both years of the extension study.124 Two further 
studies are still running. ONWARD (Oral cladribine added 
oN to Rebif new formulation in patients With Active Relaps-
ing Disease) is a 96-week, double-blind, placebo-controlled, 
Phase IIb study, in which oral cladribine is added to IFN-β1a 
(subcutaneous three times weekly, 44 µg).125 The primary 
end-point is the safety and tolerability of oral cladribine 
compared with placebo in patients with active MS (RRMS 
and SPMS with superimposed relapses). Clinical and MRI 
end-points are secondary outcome measures in this study. 
ORACLE (ORAl CLadribine in Early MS) is a randomized, Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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double-blind, placebo-controlled study of 600 subjects with 
CIS and positive MRI brain scans. The aim is to assess the 
effect of early treatment with oral cladribine in delaying 
the development of definite MS. The design provides for 
three arms (1:1:1 ratio) receiving one of two different dosage 
regimens of cladribine tablets or matching placebo: in the 
first year two or four treatment cycles are scheduled, with 
each cycle consisting of once daily administration for four 
to five consecutive days; in the second year, two treatment 
cycles are to be administered to all patient groups. Patients 
will be treated for 96 weeks or up to the time when they 
experience a second attack, in which case they would be 
offered an open-label treatment with IFN-β1a 44 µg three 
times a week for a 96-week maintenance treatment period. 
Patients who do not convert to clinically definite MS within 
the initial 96-week period of the study will be eligible to enrol 
in a 96-week long-term follow-up treatment period.126
Tolerability and safety
A review of adverse events in all MS subjects enrolled 
in cladribine studies,63 both for oral and parental prepara-
tions, found adverse events were increased in cladribine-
treated groups. Neoplasms and serious adverse events were 
reported, respectively, in 3.7% and 12.9% of all cladribine-
treated subjects compared with 1.7% and 8.1% of placebo-
treated subjects. Eighteen common adverse events were 
found to have at least 2% greater incidence within cladribine-
treated than placebo-treated subjects: headache (25.8% vs 
19.4%); lymphopenia (21.3% vs 1.7%); upper respiratory 
tract infection (15.9% vs 11.3%); nasopharyngitis (13.7% vs 
11.5%); nausea (13.4% vs 11.1%); fatigue (10.0% vs 7.9%); 
back pain (9.3% vs 7.1%); depression (7.8% vs 4.0%); 
leucopenia (5.9% vs 0.6%); pyrexia (5.7% vs 2.7%); injec-
tion site bruising (4.5% vs 1.7%); rash (4.4% vs 1.5%); MS 
(3.9% vs 1.0%); alopecia (3.3% vs 1.3%); lymphocyte count 
decreased (3.5% vs 0.0%); muscular weakness (3.2% vs 
1.0%); and herpes zoster (2.9% vs 0.2%).
Lymphopenia was a dose-dependent side effect of cladrib-
ine, occurring in 6.1% at lower doses (0 to 1.75 mg/kg); 
15.2% for doses from 1.75 to 3.5 mg/kg; 20.6% for doses 
from 3.5 to 5.25 mg/kg; and 28.4% at higher doses (5.25 to 
7.0 mg/kg).
In the CLARITY study the reported adverse events were 
more frequent in the cladribine groups and included lym-
phocytopenia (21.6% in the 3.5 mg group and 31.5% in the 
5.25 mg group, vs 1.8% in placebo patients), herpes zoster 
(eight and twelve patients, respectively, vs none in placebo 
patients), and one patient who was treated with cladribine 
had reactivation of latent tuberculosis and died.123 A concern 
with using cladribine is the risk of malignancies, which were 
elevated in the cladribine-treated groups in the CLARITY 
study whereas none occurred in the placebo group, which is 
atypical in a study of this size.123 Cladribine has been used 
extensively in hairy cell leukemia (HCL) where it is still 
unclear whether the higher risk of subsequent malignancy is 
related to the use of cladribine or hairy cell leukemia itself.127 
These concerns will be addressed more fully when the results 
of ONWARD and ORACLE become available.
Fingolimod
Clinical efficacy
Fingolimod has been recently licensed for use in RRMS by 
the US Food and Drug Administration (FDA).128 Evidence of 
its effectiveness is based on studies in animal models,70,129,130 
Phase II trials131–133 and in particular two Phase III trials.
In the first,134 1272 subjects with RRMS were enrolled to 
receive daily oral fingolimod 0.5 mg, 1.25 mg, or placebo. 
Over 24 months of 1033 subjects who completed the study, 
those receiving placebo, 0.5, or 1.25 mg of fingolimod 
showed an annualized relapse rate of 0.40, 0.18, and 0.16, 
respectively, and a cumulative probability of disability pro-
gression, confirmed after 3 months, of 24.1%, 17.7%, and 
16.6%, respectively. Fingolimod significantly reduced the 
risk of disability progression over the 24-month period at 
doses of 0.5 mg and 1.25 mg with an HR of 0.70 and 0.68, 
respectively, versus placebo. Enhancing lesions, lesion 
load, and brain atrophy on MRI were also significantly 
reduced over the 24-month period in treated versus placebo 
patients.
In the second Phase III study,135 which compared the 
efficacy of oral fingolimod with intramuscular IFN-β1a, 
1292 subjects with RRMS were enrolled to receive daily 
oral fingolimod 0.5 mg, 1.25 mg, or IFN-β1a 30 µg weekly. 
Notably, subjects were allowed to have failed IFN-β prior 
to enrolment and thus could be re-exposed to a therapy they 
had failed – IFN-β. Over 12 months 1153 subjects completed 
the study. Patients receiving IFN-β1a, fingolimod 0.5 mg, or 
1.25 mg showed an annualized relapse rate of 0.33, 0.16, and 
0.20, respectively, but no significant differences were seen 
in disability progression. Enhancing lesions, lesion load, and 
brain atrophy on MRI were also significantly reduced over the 
12-month period in fingolimod versus IFN-β1a patients.
Tolerability and safety
In the placebo-controlled fingolimod study the incidence of 
lower respiratory tract infections was higher in the fingolimod Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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than the placebo group, infections occurring in 9.6% patients 
receiving 0.5 mg and 11.4% patients receiving 1.25 mg of 
fingolimod versus 6.0% patients receiving placebo. The 
fingolimod group also had a dose-dependent slowing of the 
heart rate and a higher incidence of atrioventricular conduc-
tion block at the time of the first dose. A higher occurrence 
of macular edema was also observed, which resolved with 
discontinuation of the drug, as well as the frequent elevations 
in liver-enzyme levels.
In the comparator study versus IFN-β, 2 fatal cases of 
herpes infection occurred. One was a case of herpes simplex 
encephalitis who was originally given a course of intravenous 
methylprednisolone for an MS relapse and the second was 
a case of disseminated primary varicella zoster infection in 
a patient with a negative baseline varicella zoster antibody 
titer who was exposed to a child with chicken pox during an 
8-day course of corticosteroids (intravenous and then oral 
methylprednisolone) for a MS relapse.
BG-12
Clinical efficacy
In light of its mode of action and effectiveness in psoriasis, 
a pilot study investigated the safety and efficacy of oral DMF 
and ethylhydrogen fumarate in MS patients.82 This was a 
prospective, open-label study conducted in 10 patients with 
RRMS. The study medication was titrated over 9 weeks up 
to a dose of 240 mg three times daily. The study medication 
significantly reduced the mean number of enhancing lesions 
after 22 and 70 weeks of treatment. A Phase IIb double-
blind, placebo-controlled, dose-ranging, multinational study 
was conducted involving 257 RRMS patients randomized 
1:1:1:1 ratio to receive oral DMF 120 mg once daily, 120 mg 
three times daily, 240 mg three times daily, or placebo for 
24 weeks.136 During the subsequent 24-week safety extension 
period all patients received DMF, those receiving placebo 
starting 240 mg three times daily. The 240 mg three times 
daily arm met the primary end-point, with a significant reduc-
tion in the total number of enhancing lesions by 69% as well 
as the number of new or enlarging T2-hyperintense lesions 
and the number of new T1-hypointense lesions compared 
with placebo.
Two Phase III studies are underway aiming to determine 
the safety and efficacy of oral fumarate in RRMS. The first, 
DEFINE (Determination of the Efficacy and safety of oral 
Fumarate IN rElapsing-remitting MS), is a double-blind 
study in which 1011 patients have been randomized 1:1:1 to 
receive oral DMF 240 mg three times a day, twice a day, or 
placebo, completed in January 2011. The second, CONFIRM 
(COmparator and aN oral Fumarate In Relapsing-remitting 
MS), is a study comparing two dosages of oral DMF and 
subcutaneous GA 20 mg once daily, 1232 patients affected 
by RRMS have been enrolled to receive 1:1:1:1 oral DMF 
240 mg three times daily, twice daily, GA, or placebo. Both 
trials have a treatment period of 96 weeks. After 1 year of 
treatment patients who experience sustained disability pro-
gression or one relapse after 24 weeks in DEFINE and two 
in CONFIRM can optionally switch to any MS therapy as 
open-label rescue therapy.
Tolerability and safety
In the pilot, open-label study82 the most common adverse 
events reported were gastrointestinal symptoms (diarrhea, 
cramps, nausea) and flushing, which were experienced by 
almost all patients but decreased after the first 6 weeks of the 
treatment. In the much larger Phase IIb study,136 the common 
adverse events were flushing, headache, nasopharyngitis and 
nausea. No difference in the frequency of infections was 
seen between all groups. Although only recently studied 
in MS, the use of this class of drugs in psoriasis has shown 
them to be generally well tolerated and safe agents for up 
to 14 years.137
Laquinimod
Clinical efficacy
Laquinimod is effective in experimental studies using 
animal MS models99,100,103 and has shown neuroprotective 
capacity.105,138,139
In the Phase II study140 209 RRMS patients were random-
ized to receive two different doses of laquinimod, 0.1 mg 
or 0.3 mg, compared with placebo, as three daily tablets 
for 24 weeks. In this multicenter, double-blind, randomized 
trial, patients receiving laquinimod 0.3 mg had a significant 
44% reduction in mean cumulative number of active lesions 
versus placebo. No differences were found in relapses and 
disability between the three groups.
In the double-blind, placebo-controlled Phase IIb study,141 
306 patients affected by RRMS with at least one enhancing 
lesion on the screening MRI were enrolled to receive oral 
laquinimod 0.3 mg, 0.6 mg, or placebo, in a 1:1:1 ratio, for 
36 weeks. The results showed a 40.4% reduction of enhanc-
ing lesions in the last 4 months MRI scans in the group receiv-
ing the higher dosage of laquinimod versus placebo.
Two Phase III trials are being conducted. The first, 
ALLEGRO (Assessment of oral laquinimod in preventing 
progression of MS), is a double-blind study that recruited 
1000 patients with RRMS who were randomized to receive Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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laquinimod 0.6 mg once a day or placebo for 24 months. 
The study demonstrated a significant reduction in annualized 
relapse rate compared with placebo and showed a significant 
reduction in disability progression, though the extent of 
these effects are not yet published.142 The second Phase III 
randomized, double-blind, parallel-group, placebo-controlled 
study, BRAVO (Benefit-Risk assessment of AVOnex 
and laquinimod), aims to compare the effect of daily oral 
laquinimod 0.6 mg with placebo and with IFN-β1a (Avonex) 
administered intramuscularly 30 µg weekly. Recruitment was 
completed in June 2009 and the results are awaited.
Tolerability and safety
In the Phase II study140 there was no significant difference 
in adverse events between the groups. Two serious adverse 
events, breast cancer and acute tonsillitis, were reported in 
the laquinimod higher dosage group, as well as a mild and 
transient increase in liver function tests. In addition a small 
dose-related elevation of erythrocyte sedimentation rate was 
also noted. In the Phase IIb randomized controlled trial,141 
again transient and dose-dependent increases in liver enzymes 
were noted. A case of Budd–Chiari syndrome occurred after 
1 month of the higher laquinimod dosage exposure in a 
patient with underlying hypercoagulability (heterozygosis 
for factor V Leiden mutation). Chest pain occurred in four 
patients receiving 0.6 mg and in two patients receiving 
laquinimod 0.3 mg. Arthralgia was reported by two patients 
in the 0.6 mg group and by four in the laquinimod 0.3 mg 
group. Viral infections, herpes simplex, and herpes zoster 
were more frequent in 0.3 mg laquinimod arm.
Teriflunomide
Clinical efficacy
Preclinical testing of teriflunomide has been found to be 
effective in an EAE-MS model.143 The initial results of a clini-
cal trial in MS have been recently presented.144–147 TEMSO 
(Teriflunomide in Reducing the Frequency of Relapses 
and Accumulation of Disability in Patients With Multiple 
Sclerosis) is a Phase III 2-year randomized, double-blind, 
placebo-controlled study that included 1088 relapsing MS 
patients. Patients were randomized to placebo or terifluno-
mide, 7 mg or 14 mg, once daily. Both doses of teriflunomide 
significantly reduced annualized relapse rate by 31% versus 
placebo. The 12-week sustained risk of disability progression 
was also significantly reduced by 30% for the 14 mg and 24% 
for the 7 mg dose. Teriflunomide also significantly reduced 
the lesion load at MRI by 39% and 67% at the 7 and 14 mg 
doses relative to placebo.
TENERE (Comparing the Effectiveness and Safety 
of   Teriflunomide and Interferon Beta-1a in Patients With 
Relapsing Multiple Sclerosis) is a further randomized, 
  parallel-group, single-blind study comparing the   effectiveness 
and safety of the two doses of teriflunomide (7 and 14 mg) 
versus IFN-β1a 44 µg three times a week in 300 patients with 
RRMS. The objective is to make a head-to-head comparison 
over 1 year treatment with “time to failure” as primary end-
point, defined as the first occurrence of relapse or permanent 
study treatment discontinuation for any cause, whichever 
comes first. This study is expected to be completed by the 
end of 2011. TOPIC is an international, multi-center, random-
ized, double-blind, placebo-controlled, parallel group study 
evaluating the efficacy and safety of 2 years’ treatment with 
teriflunomide once daily at 7 mg and 14 mg versus placebo 
in approximately 780 CIS patients. The primary outcome of 
this study is the reduction of time to conversion to MS. This 
study is expected to be completed in 2015.
Tolerability and safety
In the recently presented preliminary results of TEMSO, no 
serious opportunistic infections occurred in patients treated 
with teriflunomide, and there was no difference in the seri-
ous infections between the groups, occurring in 2.2% of 
placebo, and in 1.6% of the 7 mg and 2.5% of the 14 mg 
groups.144–147
Patient-focused perspectives
A major issue with therapies in MS is that it is not clear to 
date whether they benefit subjects in the longer term and 
whether they fulfil the patients’ perception of benefit. The 
current medical aim of therapy is to prevent relapses with 
the ultimate intention of preventing progressive neurological 
deterioration that may or may not occur in the future. This 
means that therapies may have no beneficial effects to the 
subject other than a future “lack of event”.
In terms of baseline neurological symptoms therapies such 
as GA and IFN-β have shown a beneficial affect on health-
related quality of life (HR-QOL) in some subjects.148,149 This 
has to be balanced against a discontinuation rate of 28% to 
41%,150 principally due to adverse effects (52%), physician-
assessed disease progression (40%), and patient perceived 
ineffectiveness (20%). Similar to the findings of a Cochrane 
review of IFN-β1a in randomized controlled trials25 adher-
ence to therapies including GA and IFN-β is about 75% 
over an average of 31 months. Adherent patients had shorter 
disease length and shorter duration of treatment together 
with a better quality of life.151 Subjects failing to respond to Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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  treatment and dropping out would explain why those who 
adhere long-term to standard therapies such as IFN-β can 
apparently benefit from therapy in open studies.152 More 
intense therapies such as natalizumab, especially when sub-
jects have rapidly evolving severe RRMS, have a favorable 
affect on disability153 as well as more extensive benefits on 
HR-QOL.154
As therapies are being initiated earlier, as in CIS or even 
RIS stages, however, subjects will have no ongoing neuro-
logical symptoms or impairment. Thus any side effects that 
affect QOL will have an impact on their continued use. For 
the current injectable therapies in MS to be beneficial they 
need to be used long term, and this is proving a problem in 
RRMS. In CIS and RIS they will need to be used for much 
longer in essentially asymptomatic subjects, and thus one 
might expect higher rates of dropout. Some of these issues 
will arise as a result of long-term administration of any 
therapy, including oral therapies.
Drug administration
Therapies must be tolerated in terms of the modality of 
drug administration. This means that injectables are at an 
immediate disadvantage compared with oral administration. 
Subcutaneous and intramuscular injections are a discomfort, 
can be painful, and are currently rejected by some patients 
on that basis alone. IFN-β and GA commonly cause skin 
site reactions that can be irritating only but can also cause 
scarring of tissue, leading to lipoatrophy and lipohypertrophy 
that can make continued administration difficult.155 Very 
occasionally, injections, usually as a result of poor injection 
technique, cause skin infections that require treatment with 
antibiotics. Natalizumab requires intravenous administration 
and entails a risk of allergic reactions that require admission 
to hospital for a short period with implications for funders 
and for resource allocation.
The oral therapies have immediate benefits over inject-
ables in terms of administration; however, subjects prefer 
oral administration but only if efficacy is not compromised.156 
Fingolimod is a daily therapy. However, cladribine is admin-
istered only every 6 months, and thus has further potential 
advantages.
Day-to-day
The injectable IFN-β can cause transient flu-like symptoms. 
However, in some cases side effects can be ongoing. These 
include muscle aches and spasticity in 15% of subjects157 
and low mood has been reported,158 whereas GA has minimal 
day-to-day side effects. These side effects are an issue in the 
longer term. Nevertheless, it is not clear how day-to-day 
side effects contribute to the 52% of side-effect dropouts as 
opposed to drug administration issues.150
Oral therapies emerging in 2011 have few day-to-day 
issues, though they are yet to be extensively used. Fingolimod 
can cause nausea and headaches but is reported to be well 
tolerated.135 No significant day-to-day issues are associated 
with use of cladribine.123
Risk of infections
Therapies that impair the immune system function can put 
the user at risk of infections. Infection themselves represent 
a significant issue for people with MS, not only by requiring 
treatment themselves, but also by affecting MS symptoms in 
ways that often mimic a relapse of MS.159 In MS, urinary dys-
function increases as disability increases,160 making urinary 
tract infections a major problem as disability accumulates.
There is minimal risk of infections with IFN-β and GA. 
The original reports found no increased risk of infections 
with natalizumab use. However, the emergence of PML and 
other opportunistic infections has demonstrated that there is 
impaired immunity in subjects on this therapy and has sug-
gested that rigorous long-term follow-up is appropriate.161
Oral therapies such as fingolimod and cladribine have 
increased rates of infections. Fingolimod increased lower 
respiratory tract infections compared with placebo134 and 
produced more serious herpes virus infections, even though 
this was not replicated in the comparator trial.135   Cladribine 
increased the risk of infections overall and of herpetic 
infections in particular.123 These issues are a concern as 
the schemes of administration do not require subjects to 
automatically attend clinical follow-up frequently, and 
thus infections could become more serious if not managed 
proactively.
Considering the mechanism of action of the available 
drugs (IFN-β, GA, and natalizumab) and the new oral thera-
pies (fingolimod, cladribine, terifluonamide, laquinimod, 
and BG12), it would be expected that there may be some 
similarity in side effects between drug groups (Figure 4). 
Natalizumab, fingolimod, and cladribine potentially reduce 
lymphocyte numbers at the site of action whereas terifluon-
amide, laquinimod and BG12 are more similar to IFN-β/GA. 
The current limited knowledge of side effects does seem to 
support this distinction (Table 2).
Life-threatening adverse events
Major risks from therapy also need to be considered as 
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IFN-β has few risks apart from liver damage, which is rare 
and can be attenuated by following monitoring guidelines,30 
and GA has no major risks.
Natalizumab can cause reactivation of the JC virus caus-
ing PML.162 This life-threatening condition was initially 
fatal in all cases but can now be managed by using plasma 
exchange to remove natalizumab, allowing the host immune 
system to reconstitute and to clear the virus, although at a risk 
of inducing the immune reconstitution syndrome (IRIS).162 
An emerging risk-management strategy is evolving around 
the finding that those who have never had the JC virus infec-
tion can not get PML unless they develop a new infection. The 
development of an assay to test for the presence of JC virus 
means that the risk of this complication can be stratified.163 
The risk of malignancy with natalizumab is not elevated; 
although initial links were made with melanoma this has not 
being confirmed in large populations.164
Oral therapies have shown evidence of life-threatening 
adverse events in randomized controlled trials. In the 
  placebo-controlled fingolimod study, two subjects died due to 
disseminated herpes infections134 and in the comparator study 
there was an increased frequency of localized skin cancers 
in the fingolimod-treated group.135 Cladribine was associ-
ated with an increased risk of malignancy with none in the 
placebo group and 10 (1.1%) in the treated group.   Notably, 
five were benign uterine leiomyomas, the significance of 
which is as yet unclear.123
These issues with oral therapies hinted at in the random-
ized controlled trials (Table 2) require further information 
to be collected post-licensing to quantify the existence and 
extent of any association. In the light of the prolonged disease 
course in MS, long-term side effects need to be quantified in 
order to optimize treatment pathways.
Pregnancy
This is a significant consideration as MS presents more com-
monly in childbearing women than any other group. It is a 
key issue for young women considering disease-modifying 
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Figure 4 Simplified overview of postulated mechanism of action of standard injectables and new oral therapies. Fingolimod and cladribine reduce available circulating 
lymphocytes by blockade of lymphocyte egress from lymph nodes (fingolimod), by cytotoxicity and depletion (cladribine). Natalizumab acts by blockade of adhesion and 
transmigration across the blood–brain barrier. All three drugs (fingolimod, cladribine, and natalizumab), indirectly (fingolimod and cladribine) or directly (natalizumab), reduce 
the number of lymphocyte in the central nervous system (CNS). In contrast, IFN-β and glatiramer acetate (GA) shift the balance of lymphocytes and modulate cytokine 
secretion. The newer oral therapies, terifluonamide, laquinimod, and BG-12, do not reduce lymphocytes in the CNS and appear to act in a similar way to IFN-β and GA by 
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therapy, as MS itself has no effect on pregnancy outcomes 
and pregnancy can have a beneficial effect on the disease, 
though it has to be balanced against deterioration after 
delivery.165 Of the standard therapies, GA has not caused 
major concerns in pregnancy. IFN-β is associated with 
an abortive effect at 40 times the recommended dose.166 
GA can be continued in pregnancy (FDA category B) but 
it is currently recommended that IFN-β be halted prior to 
pregnancy or if the patient becomes pregnant (FDA cat-
egory C). Recent work in 88 pregnancies exposed to IFN-β 
showed no evidence of any fetal complications, malforma-
tions, or developmental abnormalities.165 Natalizumab has 
shown evidence of fetotoxicity in animal studies. Without 
controlled data in pregnancy it is recommended only when 
benefit outweighs risk (FDA category C). However cohort 
studies have confirmed that subjects can have a successful 
pregnancy after natalizumab.153
Animal data have revealed evidence that at doses equiva-
lent to the recommended dose in humans, cladribine can 
be teratogenetic, embryotoxic, and fetotoxic, can increase 
resorptions and reduce litter size, and can cause fetal death. 
As a result cladribine has been assigned to pregnancy cat-
egory D by the FDA. There are no anecdotal or controlled 
data from human pregnancy and there is no evidence of 
teratogenicity in humans. However other drugs that inhibit 
DNA synthesis have been teratogenic in humans.
The S1P1 receptor blocked by fingolimod is involved in 
vascular formation, and consistent with this fingolimod has 
been found to produce vascular defects in one animal spe-
cies, including persistent truncus arteriosus and ventricular 
septal defect.
Fifty-two pregnancies have been reported in fingolimod 
clinical trials in MS as well as three pregnancies in the 
renal transplant population.167 The incidence of spontaneous 
abortion was consistent with expected rates. A single mal-
formation has been reported, unilateral congenital postero-
medial bowing of the tibia, but it was not clearly related to 
fingolimod. However, given the findings in animals, the use 
of fingolimod in women who are or may become pregnant 
should be considered only if benefit is deemed to exceed 
potential risk to the fetus. Women considering pregnancy 
should stop fingolimod for at least 2 months.
Place in therapy in comparison with 
conventional treatment options
The efficacy of oral therapies in reducing relapse rates places 
them a step above the standard injectables, IFN-β and GA, 
but below natalizumab and mitoxantrone.
However, there are some concerns about the RRMS 
populations in which the recent oral trials were conducted, 
which were different from those of the IFN-β/GA studies 
in terms of baseline relapse rate (Figure 3). This is notable 
in that the extent of relapse reduction in natalizumab com-
parator studies showed a reduction in relapse rates of 45% 
by adding natalizumab (IFN-β1a: annualized relapse rate 
[ARR] 0.75 vs IFN-β1a + natalizumab: ARR 0.3442), which 
is similar (48%) to that seen in the fingolimod comparator 
study (IFN-β1a: ARR 0.33 vs fingolimod 1.25 mg daily: 
ARR 0.16).135 However, the comparative study currently 
available for fingolimod,35 though it recruited a proportion of 
IFN-β failures, would indicate that it is more effective than 
IFN-β and, by implication, GA. Because comparator studies 
using cladribine versus IFN-β are not yet available, at this 
point cladribine is lacking some supportive data. However, no 
direct studies have yet been performed with either fingolimod 
or cladribine versus GA.
The key question is whether oral therapies will take the 
place of IFN-β/GA or mitoxantrone/natalizumab. If the 
decision was based solely on efficacy and mode of adminis-
tration they would replace IFN-β/GA. However IFN-β/GA 
are safe therapies, and even though subjects may experience 
ongoing side effects, these medications are likely to remain 
first-line offerings for some time (Table 3). In subjects with 
no evidence of ongoing disease activity on IFN-β/GA there 
is no reason to proactively change therapy until more infor-
mation on side effects of oral treatments becomes available. 
In females with MS who wish to become pregnant in future 
GA is currently favored, but with the knowledge that IFN-β 
can be stopped and pregnancy can be successful, this drug 
can also be used. Increasing experience of natalizumab in 
pregnancy might suggest that it can be used like IFN-β and 
stopped prior to pregnancy.
The key determinants that will affect the prescription 
of oral therapies in early demyelinating syndromes appear 
to be side effects and risks. Natalizumab is not used in 
the early demyelinating syndromes such as RIS, CIS, and 
  “McDonald criteria” MS where the prognosis is unclear 
because of concerns about side effects. In fact serious side 
effects for cladribine and fingolimod appear at this point 
to be higher than natalizumab’s risk of PML (Table 2). 
Though further data are needed on long-term side effects 
with oral therapies, successfully stratifying risk in subjects 
considering natalizumab by the antibody test for JC virus 
could significantly reassure patients and physicians about 
its safety in low-risk patients. This could weaken the argu-
ment for using oral therapies, as a more effective, equally Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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safe agent would be available, and then their only advantage 
would be the oral formulation. Taking into consideration the 
current perceived risk of therapy by licensing agencies as an 
indication, it would appear that orals may be recommended 
by some health systems in “McDonald criteria” MS. Their 
use does not appear justifiable in CIS or RIS at this point 
without direct trial evidence (Table 3).
In more aggressive MS the evidence for efficacy of 
oral agents may not support the delay in initiating effective 
therapy, given that natalizumab has a track record of effi-
cacy, and although it has side effects they are well known 
and with stratification the risk profile could be significantly 
improved. Furthermore, competition from new emerging 
“immune resetting” treatments such as alemtuzumab,9 and 
mesenchymal or hematopoietic stem cell transplantation168 
are likely to arise as potential therapies of choice in more 
severe, treatment-resistant forms of disease that still present 
inflammatory features.
Conclusion
Oral therapies will unquestionably have a major impact on 
the treatment of RRMS. They are attractive to both patients 
and health care providers in that they avoid injection-related 
discomfort and adverse events and reduce the costs of admin-
istering them.
Efficacy matters to patients and, together with the way 
of administration, oral drugs represent a strong new entry 
to the relapse-modifying therapy market. Further data are 
required on their long-term safety profile to establish their 
exact role in treatment of different forms of MS (early vs 
established, mild vs severe) and their placement in relation 
to the existing treatments.
Current data support their gradual introduction as an 
option for patients with RRMS who decline, opt out of, or fail 
to adequately respond to injectable treatments. Appropriate 
programs for monitoring adverse events are warranted.
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